Title of the cohort
The Cognitive Function and Ageing Studies
Acronym for cohort
CFAS
Name of Principal Investigator
| Title | Prof |
| First name | Carol |
| Last name | Brayne |
Address of institution where award is held
| Institution | Institute of Public Health, University of Cambridge |
| Street Address | Robinson Way |
| City | Cambridge |
| Postcode | CB2 0SR |
Country
- United Kingdom
Website
http://www.cfas.ac.uk
Contact email
1. The cohort includes, or expects to include, incidence of the following conditions
- Alzheimer’s disease and other dementias
- Parkinson’s disease
- Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible
- Already possible
2a. Stated aim of the cohort
To find out how common dementia and associated conditions are in England and Wales and also, how many new cases of dementia develop each year
2b. Features distinguishing this cohort from other population cohorts
3a. i) Number of publications that involve use of cohort to date
190
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
http://www.cfas.ac.uk/pages/publications/searchpub.asp
3c. Information (i.e. research findings) expected to be gained from the population cohort
4a. Study criteria: age range of participants at recruitment
| Age in years from: | 65 |
| To (‘until death’ if applicable): | No limit |
4b. Study criteria: inclusion criteria
The CFAS are population based studies of individuals aged 65 years and over living the community, including institutions. The fieldwork for this study began in 1991.
4c. Study criteria: exclusion criteria
N/A
5. Size of the cohort (i.e. number of participants enrolled)
- 10,001 – 15,000 participants
6a. Measures used to characterise participants
6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
- No
7. Study design
- Prospective cohort
- Longitudinal
- Other (please specify)
- The follow-up has been determined by funding and the design of associated bolt-on studies.
8. Cases matched by
- Other health assessment (specify) / N/A
9a. Does the study include a specialised subset of control participants
- No
9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date
01-01-1989
10a. ii) Data collection end date
10a iii) Data collection for this study is
- Data analysis ongoing
10b. Plans to continue the cohort study beyond the current projected end date
- Yes – funding applied for
11. Data collected
- Only through the study
12. System in place to enable re-contact with patients for future studies
- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)
13a. Format and availability of data stored in a database
| Yes/No | % available | |
| Data summarised in database | ||
| Database is web-based | ||
| Database on spreadsheet | Yes STATA | |
| Database is on paper | ||
| Other (specify) |
Language used:
English
13b. Format and availability of data held as individual records
| Yes/No | % available | |
| Data held as individual records | ||
| Data is web-based | ||
| Data held on computer based records | Yes | |
| Data held on cards | ||
| Other (specify) |
Language used:
English
14a. Are data available to other groups
Yes
14b. Access policy/mechanisms for access if data are available to other groups
- Apply to PI or co-ordinator at resource
- Access Committee mechanism
15. Data sharing policy specified as a condition of use
- Data made publicly available after a specified time point
16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA
- Post-mortem donors: brain
- Living donors:blood
16b. ii) Form available tissues/samples/DNA are supplied in
- Primary Samples: Stabilised samples (frozen or fixed)
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups
- No